PSMA PET–CT imaging will become incorporated into everyday practice for prostate cancer management and requires the clinician, in collaboration with a nuclear medicine physician, to interpret the findings appropriately when recent therapeutic advances have been approved in a conventional imaging era. This evidence concerns the gene FOLH1 and prostate carcinoma.